Loading
Governments and philanthropists commit large payments for whoever achieves a verified jump in ten-year cure rates for a specific cancer, however they do it.
Drug incentives reward incremental progression-free survival in late-stage disease; nothing rewards curing. Prize and advance market commitment mechanisms have worked for vaccines and longitude. The proposal is a set of cure prizes, each defined as a verified increase in a specific cancer's five- or ten-year relapse-free survival in a defined population (for example, pancreatic adenocarcinoma stage II, glioblastoma, metastatic triple-negative breast cancer), funded by pooled public and philanthropic commitments, awarded on registry-verified population outcomes with pro-rata payments for partial progress and open licensing conditions.
Shares Incentives reward me-too drugs and marginal gains, Glioma & glioblastoma, Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma.
Shares Incentives reward me-too drugs and marginal gains, Funding follows fashion, not burden, Pancreatic ductal adenocarcinoma.
Shares Funding follows fashion, not burden, Glioma & glioblastoma, Pancreatic ductal adenocarcinoma.
Shares Funding follows fashion, not burden, Pancreatic ductal adenocarcinoma.
Shares Incentives reward me-too drugs and marginal gains, Funding follows fashion, not burden.
Shares Funding follows fashion, not burden, Pancreatic ductal adenocarcinoma.
Shares Incentives reward me-too drugs and marginal gains, Funding follows fashion, not burden.
Shares Incentives reward me-too drugs and marginal gains, Funding follows fashion, not burden.